Abstract The inherited cardiac diseases hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy (DCM) can both be caused by missense mutations in the TPM1 gene which encodes the thin filament regulatory protein a-tropomyosin. Different mutations are responsible for either HCM or DCM, suggesting that distinct changes in tropomyosin structure and function can lead to the different diseases. Various biophysical and physiological approaches have been used to investigate the structurefunction effects of the mutations, and animal models developed. The reported effects of the mutations include changes to the secondary structure of tropomyosin, its binding to actin and its position on the thin filament, and alterations to actin-myosin interactions and myofilament Ca 2? sensitivity. The latter changes have been found to be particularly consistent, with HCM mutations increasing Ca 2? sensitivity and DCM mutations in general decreasing this parameter and uncoupling the effect of troponin phosphorylation upon Ca 2? responsiveness. As well as impacting on contractility, these changes are likely to alter intracellular Ca 2? handling and signaling, and a combination of these alterations may provide the trigger for disease remodeling.
Introduction
The seminal paper by Geisterfer-Lowrance et al. (1990) from the Seidman laboratory in 1990 was the first to report that a mutation in a gene encoding a cardiac contractile protein can cause hypertrophic cardiomyopathy (HCM). After this initial finding of a missense mutation in the gene encoding b-myosin heavy chain (MYH7), mutations in other contractile protein genes were revealed to cause HCM, leading to the disorder being labeled a ''disease of the sarcomere'' (Thierfelder et al. 1994) . One of the identified genes was TPM1 (Thierfelder et al. 1994; Watkins et al. 1995) which encodes a-tropomyosin, the a-helical coiled coil dimer which lies along the length of the actin filament and plays a key role in contractile regulation (Tobacman 1996; Gordon et al. 2000; Perry 2001 Perry , 2003 . Other mutations in TPM1 were later shown to cause the phenotypically distinct disease of inherited dilated cardiomyopathy (DCM) (Olson et al. 2001 ) and mutations have also been found in patients with left ventricular non-compaction (LVNC). This review discusses the cardiomyopathy-causing mutations in TPM1, contrasts the effects of the different cardiomyopathy mutations on tropomyosin structure and function, and assesses the likely mechanisms involved in the development of the respective diseases.
Specific mutations in TPM1 cause different cardiomyopathies

Hypertrophic cardiomyopathy
HCM is an autosomal dominant inherited heart disease that results in hypertrophy of the left ventricle in the absence of other cardiac or systemic disease (such as hypertension or aortic stenosis) (Maron 2002; Watkins et al. 2011) . It is characterized morphologically by left ventricular wall and septal hypertrophy, resulting in a decreased left ventricle volume. Obstruction of the left ventricular outflow tract is present in *25 % of patients. Histologically, areas of myocyte disarray and interstitial fibrosis are characteristic of the disease. Functionally, systolic hypercontractility and impaired relaxation can cause progressive heart failure and an increased incidence of electrical conduction disturbances can lead to sudden cardiac death. HCM is the most prevalent cardiovascular single gene disorder with a reported frequency of 1:500 (Maron 2002) . The first reported TPM1 alleles to cause HCM were the missense mutations Arg175Asn and Glu180Gly that were found by linkage analysis of HCM families (Thierfelder et al. 1994) . Subsequent sequencing of TPM1 in further affected individuals detected additional mutations, and there are now at least 15 described in the current literature (Table 1) . Most of these mutations are unique and have been reported in only a single family or individual; their absence in a large number of control chromosomes (typically 400-1,000) is frequently used as evidence of their pathogenic nature, although one cannot rule out that one (or more) may be non-pathogenic, low frequency variants. Each mutation is missense causing a single amino acid substitution, and no truncation or nonsense mutations have been reported. The frequency of TPM1 mutations causing HCM is low, almost certainly no higher than 1 %: for example, a study involving 389 unrelated patients found that only three (0.77 %) had TPM1 mutations (Van Driest et al. 2003) , and another report found no TPM1 mutations at all in a cohort of 197 unrelated individuals with HCM (Richard et al. 2003) .
In common with other HCM disease genes with the exception of MYBPC3, TPM1 mutations most likely act via a dominant negative, poison polypeptide mechanism rather than via haploinsufficiency. In addition to its expression in the myocardium, TPM1 is also expressed in skeletal muscle which offers a more accessible source for biopsy. Analysis of vastus lateralis muscles from two HCM patients carrying the Asp175Asn mutation revealed equal expression of wild type and mutant a-tropomyosin proteins (Bottinelli et al. 1998) . The quantitation was aided by the anomalous migration of the mutant protein during SDS-PAGE (ca. 1 kDa lower apparent molecular mass than wild type despite a negligible calculated difference).
Dilated cardiomyopathy
DCM is characterized by increased left ventricular chamber volume and decreased systolic function in the absence of underlying coronary artery disease. Over 50 loci for inherited DCM have been characterised, with disease genes encoding nuclear, cytoskeletal and costameric proteins as well as cardiac contractile proteins (Watkins et al. 2011; McNally et al. 2013) . In 2001, mutations in TPM1 were shown to cause autosomal dominant DCM with the identification of the missense mutations Glu40Lys and Glu54-Lys (Olson et al. 2001) . With analysis of further affected families and individuals, there are now at least 12 TPM1 mutations identified to cause DCM (Table 1 ). All mutations are missense and, importantly, each has not also been reported to cause HCM in other individuals or families.
Left ventricular non-compaction LVNC is a rare cardiomyopathy characterized by prominent left ventricular wall trabeculation and intertrabecular recesses, likely arising from incomplete myocardial compaction in the embryo. Symptoms include heart failure, sustained ventricular arrhythmias and sudden death . Mutations in cardiac contractile protein genes have been reported to cause LVNC, although frequently the specific mutations are also known to cause either HCM or DCM in other individuals suggesting that LVNC represents a continuum of the other cardiomyopathy phenotypes. For example, the Glu101Lys cardiac actin mutation reported to cause apical HCM (Arad et al. 2005) and the Arg131Trp cardiac troponin T mutation associated with DCM (Mogensen et al. 2004) , have both been reported to cause LVNC (Klaassen et al. 2008) . Five TPM1 mutations have been reported in studies of LVNC patients (Table 1) . The Asp84Asn (Probst et al. 2011; Van Driest et al. 2003) and Glu192Lys (van de Meerakker et al. 2013 ) mutations also cause respectively DCM and HCM; the Arg160His (Hoedemaekers et al. 2010 ) and Lys248Glu (Probst et al. 2011 ) mutations found only in single probands, with the individual the de novo Arg160His mutation having a large dilated heart. In contrast, Lys37Glu was present in a family with LVNC and sudden death (Chang et al. 2011) .
How do the disease-causing mutations affect tropomyosin structure and function?
Given the likelihood that the cardiomyopathy mutant tropomyosins act as poison polypeptides (Bottinelli et al. 1998) , much work has been carried out to identify the specific changes in contractile regulation and protein structure caused by incorporation of the mutant proteins. In biochemical analyses, the tropomyosin used has mainly been recombinant, and most frequently a-tropomyosin expressed in Escherichia coli with a met-ala-ser N-terminal extension, which is processed to ala-ser in the bacteria. This short leader sequence has been shown to mimic the N-terminal acetylation which is present in the native protein (Monteiro et al. 1994) but not in bacterial proteins due to the lack of the required N-a-acetyltransferase complexes (or equivalent) in prokaryotes (Johnson et al. 2010 ).
Effects of cardiomyopathy mutations on tropomyosin structure
The a-helical coiled coil structure of tropomyosin is determined by the heptad repeat (abcdefg) present throughout the primary sequence, with the a and d positions being principally composed of small hydrophobic residues which interact to mediate dimerization (Perry 2001) . The b, c, e, f and g positions are most often occupied by ionic or polar residues; the coiled coil can be further stabilized by salt bridges between e and g residues, and b, c and f positions may form intermolecular interactions with actin or troponin. The length of the tropomyosin molecule may be divided into seven quasiequivalent repeats of c. 40 amino acids, each corresponding to an actin binding site (McLachlan et al. 1975; McLachlan and Stewart 1976) (Fig. 1) . Each repeat may be further split into N-terminal (a) and C-terminal (b) halves, with the residues in the a bands hypothesised to be interacting with actin when the thin filament is in the blocked position and the b bands hypothesised to be interacting in the closed and open positions (Holthauzen et al. 2004; McLachlan and Stewart 1976) . We note that recent structural work suggests that the movement of tropomyosin over actin is via a sliding rather than rolling mechanism and the residues in the b bands may not interact with actin (Behrmann et al. 2012) . Table 1 Table listing There is no consistent pattern for the cardiomyopathy mutations (either in general or for mutations causing a specific phenotype) to affect residues within a particular actin-binding repeat or a specific residue in the heptad repeat ( Fig. 1 ; Table 1 ). Some mutations lie within known troponin T-binding regions (175-190 and 258-284) (Jagatheesan et al. 2004) , and two alter residues (Asp58 and Glu62) identified to interact with actin (Li et al. 2011) (Fig. 1) . The Met281Thr and Ile284Ala mutations affect residues at the extreme C-terminus that are involved in end-to-end interactions of neighbouring tropomyosins (Murakami et al. 2008) ; additionally, they are adjacent to the Ser283 phosphorylation site and the mutations may affect Ser283 modification.
Cardiomyopathy mutations have been reported to have different effects on actin affinity and secondary structure with no clear abnormality defining one particular class of mutation (Golitsina et al. 1997; Heller et al. 2003; Kremneva et al. 2004; Mirza et al. 2007; van de Meerakker et al. 2013; Rajan et al. 2007) . Mutations that affect dimerization have been shown to increase the flexibility of the tropomyosin molecule, and can also affect actin binding and cooperative communication during thin filament calcium activation (Golitsina et al. 1997; Heller et al. 2003) . Recent atomic force and electron microscopy studies on isolated tropomyosin molecules containing the HCM mutations Asp175Asn and Glu180Gly at the e and g positions, have shown more directly the alterations to intramolecular flexibility (Li et al. 2012; Loong et al. 2012) , whilst a further study on the same mutations predicts that altered flexibility of tropomyosin can affect residues several heptad repeats distant from the primary mutation (Ly and Lehrer 2012) . It is still unclear however, whether the mutation itself or the altered flexibility is the primary cause of altered function and actin binding. Initial work predicting surface charge of tropomyosin containing either Glu40Lys or Glu54Lys charge change DCM mutations, has shown profound alterations in net charge that covers a large proportion of the molecule in proximity to the mutation, and hence would be predicted to alter proteinprotein interaction directly (Olson et al. 2001) . However, despite the change in amino acid and heptad repeat position being the same, the cooperative unit size and primary function of the two mutations are different, likely due to their position with respect to the underlying actin monomer (Mirza et al. 2005 (Mirza et al. , 2007 , although the disparity of function could equally be due to differential effects of the mutation on the severity of alterations to molecular stiffness/flexibility. (Li et al. 2011 ) and troponin T binding regions (Jagatheesan et al. 2004) dependence of in vitro motility and actomyosin ATPase, both employing thin filaments reconstituted in vitro from purified actin, tropomyosin and troponin. In these assays, the HCM mutations Ala63Val, Lys70Thr (Heller et al. 2003) ] in the acto-myosin subfragment-1 ATPase assays. A method for depleting and reconstituting porcine myofibrils has also been used to study Ca 2? -regulation of actomyosin ATPase activity by the HCM mutants Glu62Gln, Leu185Arg and Glu180Gly; consistent with isolated filament studies, each mutant was found to give increased Ca 2? sensitivity compared with wild type myofibrils with DpCa50s of between ?0.19 and ?0.44 (Chang et al. 2005) .
Initial studies on DCM TPM1 mutations suggested that they had the opposite effect of thin filament regulation, that is they decrease Ca 2? sensitivity. The Glu40Lys and Glu54Lys mutants were both shown to give lower pCa50 values compared with wild type in acto-S1 ATPase and in vitro motility assays (Mirza et al. 2005 ) as well as in ATPase studies using tropomyosin-exchanged myofibrils (Chang et al. 2005) . Reduced Ca 2? sensitivity appeared to be a consistent trend for all DCM mutations in thin filament proteins (Chang et al. 2005; Mirza et al. 2005) , and the Asp230Asn tropomyosin mutant was also reported to fit this pattern with a large negative DpCa50 (-0.27) (Lakdawala et al. 2010) . However recent work has suggested that although reduced Ca 2? sensitivity is true of the majority of DCM thin filament mutants, there are significant exceptions, for example analysis of the Asp230Asn TPM1 mutant using baculovirus-expressed tropomyosin found it to increase Ca 2? sensitivity (Memo et al. 2013; Marston 2011) . Moreover, an apparently common functional defect of all DCM tropomyosin and troponin mutations is the inability to decrease thin filament Ca 2? sensitivity in response to PKA phosphorylation of troponin I (Memo et al. 2013) .
These biochemical analyses were conducted by comparing thin filaments reconstituted with wild type tropomyosin with those reconstituted with mutant tropomyosin. However the HCM and DCM mutations almost exclusively cause autosomal dominant disease, with affected individuals carrying one normal and one mutant allele resulting in a likely equimolar mixture of wild type and mutant protein present in the thin filaments. To model more closely the disease, some work has been carried out using thin filaments reconstituted either with a wild type/mutant mixture (Lakdawala et al. 2010; Mirza et al. 2005) or defined wild type/mutant heterodimers . These studies revealed frequently the expected intermediate molecular phenotype (Lakdawala et al. 2010; Mirza et al. 2005; Janco et al. 2012) although in some cases the heterodimer effects were similar to either wild type or mutant alone, suggesting that modeling the mutation effects simply using mutant protein alone is not a completely reliable guide ).
Effects of TPM1 mutations on myocyte and myofibre force generation, and in animal models
The effect of TPM1 mutations on the contractility of intact sarcomeres has been investigated using cardiomyocytes transfected with adenoviral vectors and using demembranated myofibre or myocyte preparations, either reconstituted in situ or from patient samples and transgenic animal models.
The group of Joseph Metzger has pioneered the use of adult rat cardiomyocytes expressing mutant contractile proteins via adenoviral vectors as models of cardiomyopathy (Michele and Metzger 2000) . Expressed tropomyosins incorporate into the contractile apparatus and represent *40 % of the total tropomyosin content (Michele et al. 1999) . Three of the four HCM mutants analysed (Ala63-Val, Lys70Thr and Glu180Gly) were shown to increase Ca 2? sensitivity of force generation whereas Asp175Asn was found to behave as wild type; it was speculated that there was a broad correlation between functional readout and disease phenotype in that families with the Asp175Asn frequently had mild disease and those with the other mutations had a significant frequency of sudden death (Michele et al. 1999) . Measurement of the kinetics of cardiomyocyte contractility upon field stimulation revealed that the Ala63Val mutant caused significant slowing of relaxation (Michele et al. 2002a) .
Bovine cardiac fibre preparations containing cardiomyopathy tropomyosin mutants have been generated using the technique of thin filament extraction and reconstitution (Kawai and Ishiwata 2006) . Those fibres containing HCM mutants (Val95Ala, Asp175Asn and Glu180Gly) were found to have increased tension at diastolic Ca 2? concentrations, and Glu180Gly had raised tension at high Ca 2? . Mutants Val95Ala and Glu180Gly (though not Asp175Asn) were found to have a higher Ca 2? sensitivity of force generation than wild type (Bai et al. 2011) . Reconstituted fibres containing Glu40Lys and Glu54Lys gave significantly decreased maximum force and similar Ca 2? sensitivity of force generation compared with wild type; the Glu54Lys mutant was calculated to give c. 15 % less force per crossbridge although for the fibres containing Glu40Lys this was similar to wild type (Bai et al. 2012) . Insight into the changes to thin filament structure conferred by tropomyosin mutations has been obtained using fluorescently-labelled proteins; when incorporated into ghost fibres, their orientation can be monitored by fluorescence polarization. HCM mutations were found to shift tropomyosin towards the open position (Borovikov et al. 2011b) whereas DCM mutations were shown to inhibit tropomyosin movement (Borovikov et al. 2009b ); these changes, along with those in the movement of actin and myosin (Borovikov et al. 2009a (Borovikov et al. , 2011a Rysev et al. 2012) , are consistent with the functional effects of both classes of mutation.
Transgenic mouse models of the HCM Asp175Asn (Muthuchamy et al. 1999 ) and Glu180Gly (Michele et al. 2002b; Prabhakar et al. 2001 ) mutations have been reported along with a DCM model of the Glu54Lys mutation (Rajan et al. 2007) , each expressing the relevant transgene under control of the a-myosin heavy chain promoter. Furthermore, rat models of the HCM Asp175Asn and Glu180Gly mutations have been created with cardiac-restricted transgenic expression (Wernicke et al. 2004) . Of the HCM mouse models, Glu180Gly is more severe with ventricular hypertrophy, fibrosis and atrial enlargement detected within one month, leading to death between months 4 and 5 (Prabhakar et al. 2001) . In contrast, the phenotype of the Asp175Asn mouse was more moderate, with patchy areas of mild ventricular myocyte disorganization and hypertrophy evident after 20 weeks (Muthuchamy et al. 1999 ). Both Asp175Asn and Glu180Gly models showed systolic and diastolic dysfunction revealed by in vivo echocardiography and in vivo haemodynamic measurements (Michele et al. 2002b; Muthuchamy et al. 1999; Prabhakar et al. 2001) . Increased Ca 2? sensitivity of force generation was shown in skinned cardiac fibres (Muthuchamy et al. 1999; Prabhakar et al. 2001 ) and isolated cardiomyocytes (Michele et al. 2002b ) from these mice. In contrast, cardiac fibres from the Asp175Asn rat displayed reduced Ca 2? sensitivity, with those from the Glu180Gly rat model behaving as wild type (Wernicke et al. 2004) . The Glu54Lys DCM model recapitulated the phenotype of dilatation and progression to heart failure, with significantly depressed systolic function presenting after one (high copy number) or three (low copy number) months. Myofilament Ca 2? -sensitivity was reduced and in 5 month old mice there was significantly reduced expression of SERCA2a and ryanodine receptor (Rajan et al. 2007) .
Analysis of heart muscle from patients with TPM1 mutations has proved difficult due to the rare occurrence of these mutations and the ethical and organizational problems in obtaining biopsy or post mortem samples. Biopsy samples of skeletal muscle, in which TPM1 is also expressed, are considerably easier to obtain however; analysis of vastus lateralis muscles from two HCM patients carrying the Asp175Asn mutation revealed significantly increased Ca 2? sensitivity of force generation in skinned fibre preparations (Bottinelli et al. 1998) . There is a single recent report of analysis of cardiac muscle tissue from a patient with a TPM1 mutation. Isometric force measurements on Triton-permeabilised cardiomyocytes revealed higher Ca 2? sensitivity compared with donor control; however, PKA phosphorylation was much lower in the mutant sample, and when phosphorylation was normalized by addition of exogenous PKA, the Ca 2? sensitivity of the mutant cardiomyocytes was not significantly different from control. In addition, length-dependent activation (comparison of the force at sarcomere lengths 1.8 and 2.2 lm) was significantly reduced in the mutant cells (Sequeira et al. 2013) .
Disease pathways
How are the changes in tropomyosin structure-function revealed in the biophysical studies responsible for the different cardiac diseases caused by TPM1 mutations in the mouse models and, moreover, in the patient? While some of the alterations to myocardial contractility may be primary effects of the mutant tropomyosin, many will result from the secondary cardiac remodeling and changes at the myocyte level in response to the mutation. In HCM, the diastolic abnormalities (as well as the initially enhanced systolic function) may be at least in part due to increased myofilament Ca 2? sensitivity and higher number of cycling crossbridges which would cause incomplete relaxation at low Ca 2? concentrations. However this is also likely to be influenced by myocardial fibrosis which has been suggested to be due to activation of profibrotic signaling in non-muscle cells (Teekakirikul et al. 2010) . The higher Ca 2? sensitivity in human myocardial samples (with mutations in thick and thin filament proteins) has been shown to be also caused by lower troponin phosphorylation (Sequeira et al. 2013 ). This work has further shown a consistent feature in these samples of blunted lengthdependent activation and this may underlie aberrant endsystolic pressure-volume relation in HCM patients (Pak et al. 1998) .
Using reconstituted thin filaments and a fluorescent reporter group on troponin C, we have demonstrated that cardiomyopathy mutations in thin filament proteins (including both HCM and DCM TPM1 mutations) result in a change in actual Ca 2? affinity of the myofilaments, equivalent to the changes in Ca 2? sensitivity of contractile regulation ). Troponin C is the principal dynamic buffer of cytoplasmic Ca 2? , and has been estimated to bind approximately half of the Ca 2? ions released by the sarcoplasmic reticulum (Smith et al. 2000 cycling and changes in diastolic Ca 2? levels which may influence two aspects of the HCM phenotype-arrhythmias and hypertrophy. The former has been demonstrated using myocytes from three different troponin T HCM mouse models in which an increase in the buffering of cytosolic Ca 2? was observed using voltage clamp techniques (Schober et al. 2012) . Action potential regulation was also altered, resulting in pause-dependent triggering of arrhythmias. We hypothesise that changes in Ca 2? cycling and diastolic Ca 2? levels will also stimulate Ca 2? -dependent hypertrophic signalling pathways such as those involving calcineurin-NFAT and CamKII (Heineke and Molkentin 2006) . Effects on Ca 2? cycling are also likely to be exacerbated by the predicted effect on energetics of the hypercontractile HCM mutants, for example a lower DG of ATP hydrolysis would result in reduced SERCA activity (Ashrafian et al. 2003) .
The recent finding that DCM mutations in thin filament proteins uncouple the effect of troponin phosphorylation on Ca 2? -sensitivity may have revealed an important physiological mechanism for these mutations (Memo et al. 2013) . Troponin phosphorylation by PKA mediates faster relaxation in response to b-adrenergic stimulation and leads to increased contractile force, and uncoupling of this mechanism will result in reduced cardiac reserve.
Although phosphorylation of tropomyosin has been known to exist for many years (Ribolow and Barany 1977) , the possible physiological relevance of it has only recently started to emerge. Tropomyosin appears to be phosphorylated at Ser283 in the adult mouse heart at relatively high stoichiometry (between 0.24 and 0.39) . Expression of a non-phosphorylatable mutant (Ser283Ala) reduced overall tropomyosin phosphorylation and resulted in compensated cardiac hypertrophy with increases in expression of SERCA and in phospholamban phosphorylation at ser16 (Schulz et al. 2012) . Interestingly, expression of a Glu180Gly/Ser283Ala double mutant was found to have no hypertrophy and improved cardiac function compared with the Glu180Gly HCM mouse , suggesting a role of phosphorylated tropomyosin in mediating the effect of the HCM mutation.
Conclusion
The discovery of cardiomyopathy-causing mutations in atropomyosin has provided the contractile protein biologist with an important challenge to understand the molecular mechanisms of these significant diseases. Furthermore the locations of disease-causing mutations have given new insight into the structure-function of tropomyosin. Although the most marked and consistent differences between HCM and DCM mutants in initial biophysical characterisations have been in Ca 2? sensitivity of contractile regulation, a combination of this and other primary defects (e.g. altered actomyosin kinetics) together with secondary changes to promote remodeling are likely to underlie the different cardiomyopathies.
